查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1564934

全球新生儿筛检市场

Newborn Screening
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球新生儿筛检市场预计将达到 19 亿美元

全球新生儿筛检市场预计 2023 年为 12 亿美元，预计到 2030 年将达到 19 亿美元，2023-2030 年分析期间复合年增长率为 7.1%。消耗品是新生儿筛检报告中分析的细分市场之一，预计复合年增长率为 7.5%，到分析期结束时将达到 14 亿美元。在分析期间，新生儿筛检设备领域的复合年增长率预计为 6.3%。

美国市场预估为3.138亿美元，中国预期复合年增长率为10.6%

预计 2023 年美国新生儿筛检市场规模将达 3.138 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达到4.672亿美元，2023-2030年分析期间复合年增长率为10.6%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 3.6% 和 6.4%。在欧洲，德国的复合年增长率预计为 4.2%。

全球新生儿筛检市场 - 主要趋势和驱动因素总结

什么是新生儿筛检？

新生儿筛检是一项重要的公共卫生计划，可在婴幼儿出生后立即检测某些遗传、代谢和发育疾病。这些测试对于发现如果不及时治疗可能导致严重健康问题（例如发育迟缓、残疾甚至死亡）的疾病至关重要。透过新生儿筛检进行早期发现可以及时采取干预措施，例如药物、饮食改变和手术，以预防长期併发症并改善孩子的生活品质。

新生儿筛检计画通常包括检测多种疾病，包括苯酮尿症 (PKU)、镰状甲状腺机能低下症、囊肿纤维化。技术的不断进步正在扩大可检测疾病的范围，使新生儿筛检成为现代医疗保健的重要工具。透过及早发现这些疾病，新生儿筛检计画有助于降低婴幼儿死亡率并改善整体公共卫生。

新生儿筛检市场如何发展？

由于技术进步和筛检小组的扩大，新生儿筛检市场正在迅速发展。影响市场的主要趋势之一是串联式质谱质谱 (MS/MS) 的使用不断增加。 MS/MS 是一种可以从单一血液样本中检测多种代谢异常的技术。该技术透过实现更快、更准确和更全面的测试彻底改变了新生儿筛检。此外，包括次世代定序（NGS）在内的基因筛检技术正在整合到新生儿筛检计画中，以检测更广泛的遗传疾病，包括罕见疾病。

另一个主要趋势是新生儿筛检转向就地检验(POCT)。 POCT 设备是便携式的，可以在床边立即提供测试和结果，从而缩短诊断疾病开始治疗的时间。数位医疗平台的扩展还透过简化资料收集、分析和报告流程以及实现更有效率的新生儿筛检工作流程来帮助市场发展。这种演变使得更多的婴幼儿能够更快地接受筛检，特别是在医疗基础设施有限的地区。

哪些条件推动了新生儿筛检的需求？

苯酮尿症 (PKU) 和先天性甲状腺机能低下症代谢性疾病是最常筛检之一。如果不及早发现，这些疾病可能会导致严重的发育问题，但透过适当的干预可以显着减少其影响。囊肿纤维化和镰状细胞疾病等遗传性疾病也是筛检需求的主要驱动因素，因为早期治疗可以预防严重併发症并改善长期健康结果。

此外，溶小体贮积症 (LSD) 是一组罕见的遗传性疾病，越来越多地被纳入新生儿筛检小组。诊断技术的进步正在发现更多罕见疾病，从而实现早期治疗，改善受影响儿童的预后。需要早期饮食干预的遗传性代谢疾病的增加也导致世界各地对新生儿筛检计画的需求不断增长。

新生儿筛检市场的主要成长动力是什么？

新生儿筛检市场的成长受到多种因素的推动，包括需要早期诊断和介入的遗传和代谢疾病的盛行率不断增加。专注于扩大新生儿筛检计画的政府指令和倡议是主要驱动力，确保更多疾病纳入常规检测。技术进步，特别是质谱和基因序列测定的技术进步，也透过实现更全面、更准确的筛检来推动市场成长。

另一个重要因素是医疗保健提供者和家长越来越认识到早期检测对于预防长期健康併发症的重要性。特别是在新兴市场，随着医疗保健基础设施的改善，新生儿筛检的机会正在扩大，从而促进了市场的成长。此外，公立医疗机构和私人公司之间的合作日益加强，从而促进了先进筛检技术的传播并改善了患者的预后。

受访企业范例（11家知名企业）

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP13586

Global Newborn Screening Market to Reach US$1.9 Billion by 2030

The global market for Newborn Screening estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2023-2030. Newborn Screening Consumables, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Newborn Screening Instruments segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$313.8 Million While China is Forecast to Grow at 10.6% CAGR

The Newborn Screening market in the U.S. is estimated at US$313.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child’s quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

Select Competitors (Total 11 Featured) -

  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic PLC
  • Natus Medical, Inc.
  • PerkinElmer, Inc.
  • Trivitron Healthcare
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Newborn Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Early Detection and Prevention Drives Growth in Newborn Screening Programs Globally
    • Increasing Adoption of Genetic and Metabolic Screening Expands Opportunities for Early Diagnosis of Congenital Disorders
    • Technological Advancements in Mass Spectrometry Propel Growth in Newborn Screening for Rare Metabolic Disorders
    • Growing Focus on Early Detection of Cystic Fibrosis and Sickle Cell Disease Strengthens Demand for Newborn Screening
    • Expansion of Government-Funded Newborn Screening Programs Drives Adoption in Public Health Systems Worldwide
    • Increasing Use of Tandem Mass Spectrometry (MS/MS) in Newborn Screening Expands Precision Diagnosis Capabilities
    • Rising Adoption of DNA-Based Screening Technologies for Inherited Disorders Strengthens Market for Genomic Newborn Testing
    • Growing Demand for Point-of-Care Newborn Screening Expands Access to Early Detection in Remote and Low-Income Regions
    • Emerging Focus on Screening for Lysosomal Storage Disorders Propels Innovation in Newborn Screening Assays
    • Increasing Use of Digital Data Management Systems in Newborn Screening Programs Drives Demand for Integrated Solutions
    • Rising Demand for Expanded Newborn Screening for Immunodeficiencies and Endocrine Disorders Expands Addressable Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Newborn Screening Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dry Blood Spot Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hearing Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Immunoassays & Enzymatic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hearing Screening Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Pulse Oximetry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • FRANCE
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION